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INTRODUCTION 
Diabetes mellitus is a heterogeneous disease which is mainly 
characterized by altered cellular metabolism arising from defects in insulin 
secretion or its action or both. According to American Diabetes Association, 
Diabetes and chronic hyperglycemia results in  long- term damage to various 
organs and also cause organ dysfunction especially in the eyes, kidney, nerves, 
hearts and blood vessels and other complications such as atherosclerosis, 
coronary heart disease, diabetic retinopathy, nephropathy and neuropathy1. 
Diabetes mellitus has now become an epidemic. At present the worldwide 
incidence is 5% in the general population. Globally 100 million among the 
world's population are suffering from diabetes. The number is rampantly 
increasing and it is expected to hike upto 366 million2. Altered life style has been 
attributed for this increasing prevalence which includes decrease in physical 
activity, weight gain, stress and changes in food habbits3. In conventional 
therapy, type I diabetes is treated with exogenous insulin and type 2 with oral 
hypoglycemic agents. Though different types of oral hypoglycemic agents are 
available along with insulin for the treatment of diabetes, there is an increase 
demand by patients to use natural products with antidiabetic activity. Since time 
immemorial, patients with noninsulin-dependent diabetes have been treated 
orally in native medicine with a variety of plant extracts. In India, a number of 
plants are mentioned in ancient literature (Ayurveda) for the cure of diabetic 
conditions4. 
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Several theories have been postulated to explain the pathogenesis of 
diabetes. These encompass auto oxidation of glucose and progressive non-
enzymatic glycation of proteins. Enhanced glucose influx via polyol pathway 
which ultimately results in increased formation of glycosylation end products 
and leading cause of diabetic complications in both types 1 and 2 diabetes5. ROS 
produced by protein glycation and glucose oxidation mediates the pathogenic 
effects of high glucose.  
Reactive Oxygen Species (ROS) leads to molecular damage and cellular 
damage by directly facilitating numerous cellular stress-sensitive pathways such 
as JNK/SAPK, NF-κB, p38 MAPK, and hexosamine pathway resulting in late 
complication of diabetes6. Also ROS is responsible for β-cell dysfunction and 
insulin resistance via same pathways. Eventhough innumerable modern 
medicines are available for management of diabetes, none of them is free from 
side effects. Hence treatment of diabetes is still remains an unmet challenge. 
Antidiabetic drug, glibenclamide (GL) classified under sulfonyl ureas 
promotes insulin secretion by inhibiting  ATP-sensitive K+ (KATP) channels in 
the beta cells of pancreas.  GL (also known as glyburide) is a derivative of 
sulfonyl cyclo hexylurea. Apart from the antidiabetic property, it also possesses 
analgesic, anti-neoplastic and antiplatelet activities. Also it has vasodilatory 
effect by releasing nitric oxide which is due to its stimulatory effect on 
endothelial Ca2+ levels causing endothelium dependent relaxation activity7. 
Interestingly, research from the antioxidant studies shows that GL is efficient to 
counteract the reactive oxygen species mediated oxidative stress. The side effects 
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of oral hypoglycemic agents includes hypoglycaemia, weight gain, nausea, 
diarrhoea, hepatotoxicity, lactic acidosis, vitamin B12 deficiency, 
photosensitivity, skin rash, blood dyscrasias, cholestatic jaundice, risk of urinary 
bacterial and fungal infections. 
This leads to the search for natural products with antidiabetic activity with 
fewer side effects. Numerous herbs and plant products have been shown to 
possess anti diabetic property. Therapeutic use of plants is deployed on the 
premise that plants contain natural substances, which promote health and 
alleviate illness. Since ancient times, number of natural products has been used 
to check hyperglycemia. There is continuous search for alternative drugs. 
Therefore, it is prudent to look for options in herbal medicines for diabetes as 
well. Herbal medicines have long been used effectively in treating diseases in 
Asian communities and throughout the world8. 
The World Health Organization (WHO) has also endorsed the screening 
of herbal remedies for the management of diabetes mellitus. The ethnobotanical 
information states that nearly 800 plants has antidiabetic property. Nowadays 
numerous plant extracts have been evaluated in the field of diabetic research. It 
has ultimately resulted in many herbal products with antidiabetic activity which 
can counter the high cost and poor availability of the medicines.   
              Various natural products like Anacardium occidentale, Canavalia 
ensiformis, Catharanthus roseus, Coscinium fenestratum, Murraya koenigii and 
many other natural products has been known to possess hypoglycemic activity.   
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 Aloe vera (Barbados Aloe) is one of herbal plant shown to possess anti diabetic 
property. Aloe vera, often known as aloe or Gwar patta (Hindi), is classified 
under the family Asphodelaceae or aloe family. It has got a wide spectrum of 
acivitiy which includes wound healing, antifungal, hypoglycemic or antidiabetic, 
anti inflammatory, anticancer, immunomodulatory and gastro protective 
property. Aloe vera consists of many phytochemicals, vitamins, nutrients and 
anti-oxidants. Fresh aloe gel from the inner leaf parenchyma constitutes 96% 
water, polysaccharides (mucilage). This mucilage contains D-glucose and D-
mannose, tannins, steroid, enzymes, plant hormones, amino acids, vitamins and 
minerals9. The aloe vera gel extract also contains appreciable amount of trace 
elements (Cr, Mn and Zn). Gel from the leaves of Aloe vera is responsible for 
many of its health benefits.  
Diabetes mellitus is induced in experimental animals by using chemicals 
like Streptozotocin (STZ), a β- cytotoxin. It produces diabetes in a wide variety 
of animal species including rat by selectively damaging the insulin-secreting β-
cells of the pancreas. Intraperitoneal injection of STZ causes fragmentation of 
DNA of β-cells of pancreas which increase ADP-ribose and decreases NAD 
which ultimately leads to the destruction of β- cells resulting in the clinical 
symptoms of hyperglycemia and hypoinsulinaemia10. Oxidative stress has been 
attributed to play a significant role in the etiopathogenesis of diabetes and its 
complications11.  
To bridge the existing gap and to gain knowledge about the role of 
complimentary alternative medicine, we have performed a study on 
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antihyperglycemic effect of aloe vera gel extract in normal rats and 
streptozotocin induced diabetic rats. 
Hence, the aim of this  present study is to investigate the effects of aloe 
vera gel extract on antihyperglycemic activity.  
 
 
 
 
 
 
 
 
  
  
 
 
AIM AND 
OBJECTIVES 
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AIM 
 
To evaluate the antihyperglycemic effect of aloe vera gel extract in 
normal rats and Streptozotocin induced diabetic rats by tail venepuncture 
method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
REVIEW 
OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
“History will undoubtedly record December 20th 2006 as turning point in 
the fight against diabetes. On this day the United Nations General Assembly 
passed a landmark resolution recognising diabetes as a chronic debilitating and 
costly disease associated with major complications that pose severe risks for 
families countries and the entire world.” 
- Professor Martin Silink, President of International Diabetes Federation 
          Diseases like diabetes and coronary vascular disease (CVD) have 
increased several fold due to immense change in pace and life style. India has 
the world’s largest population suffering from Diabetes Mellitus. Worldwide 
estimates exhibit that people suffering from diabetes will rise to 366 million in 
2030 from 171 Million in 200012. In India, according to  the ‘Diabetes Atlas’ 40 
million people were registered with diabetes in 2007, which is anticipated to rise 
almost 70 million by the year of 2025, making every 5th diabetic subject in the 
world to be Indian. India has more vulnerability with a huge burden of diabetes 
due to chronic complications such as diabetic nephropathy which makes people 
more cripple13. The two most important “Life Style Diseases” commonly 
encountered in the community are diabetes mellitus and hypertension. The most 
common cause of death in the diabetic patient is heart disease14.  
Type 2 diabetes is by no means a novel disease. There is no definite 
description of diabetes found in the Corpus Hippocraticum, except inconclusive 
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descriptions by Galenus and Aretaios. It took centuries before, Thomas Willis (in 
1674) described the sweet nature of urine in diabetes and Matthew Dobson (in 1776) 
identified sugar in the urine.  In contrast, a large body of evidence points to the 
common presence and diagnosis of diabetes in ancient India and China, seemingly 
the result of genetics, lifestyle and acuity of the respective physicians.  
The Indian Sanskrit medicine literature was mentioned the characteristic 
sweet urine in diabetes likely written between 300 BC and 600 CE15. The ancient 
physicians described "sugar cane urine" (Iksumeha) or "Honey Urine" (Madhumeha 
and Hastimeha) as well as "urine flow like elephant in heat"; furthermore, they 
mentioned the observation that ants and insects rush to this type of urine16 - 
suggesting that the observations concerned true glucosuria and diabetes. The three 
cardinal symptoms are polyphagia, polyuria and polydipsia, even secondary 
sequelae of diabetes such as abscess formation, carbuncles, lassitude and floppiness. 
Suggested interventions ranged from administration of honey and sugar in patients 
with Iksumeha and Mathumeha (illogical) to the rational advice of active physical 
exercise with long marches and riding on elephants.  
EPIDEMIOLOGY 
          Against this long historical background, the recent abrupt rise in the 
prevalence of metabolic syndrome and of type 2 diabetes mellitus worldwide is 
new, and which is extremely patent in Asian countries and is particularly 
dramatic in India17,18.. This gave India the suspicious distinction of the "Diabetes 
capital of the world."  Diabetic patients  in India tend to have higher waist 
circumference despite lower body mass index, pronounced insulin resistance, 
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lower adiponectin levels and higher inflammatory markers. A high prevalence 
of the glucose intolerance and of metabolic syndrome, both  precursors of 
diabetes has been well documented in the Indian population. The prevalence of 
overt diabetes is particularly high in Indian elderly - but of great concern is the 
frequency of obesity, prediabetes and overt diabetes in the young. Diabetes is 
also particularly frequent in the rural populations of India19,20. Increasing age, 
obesity, alcohol use and a family history of T2DM independently predicted the 
development of diabetes21. 
Figure 1: Glucose homeostasis 
 
10 
 
Diabetes mellitus is an endocrine as well as metabolic disorder. It may 
also be recognised as a disorder that ultimately affects the cardiovascular system 
in the form of acceleration of atherosclerosis due to changes in the basement 
membrane of the vascular endothelium as a result of hyperglycemia, thus leading 
to the cardiovascular complications such as angina pectoris and hypertension. 
Thus it is better to consider the diabetes mellitus as endocrine, metabolic and 
cardiovascular disorder as it affects all the vital systems of the body such as eyes, 
kidney, heart, nerves and blood vessels22.  
Diabetes mellitus can be classified into many types mainly type 1 and 
type 2 diabetes. Type 1 diabetes is managed with insulin and type 2 diabetes by 
oral hypoglycemic agents and also with insulin.  
Figure 2 : Type I Diabetes 
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CLASSIFICATION23 
I. Type 1 Diabetes (beta cell destruction, usually leading to absolute 
insulin deficiency) 
A. Immune mediated 
B. Idiopathic 
II. Type 2 Diabetes (may range from predominantly insulin resistance 
with relative insulin deficiency to a predominantly insulin secretory 
defect with insulin resistance)  
 
                      Figure 3: Type II Diabetes 
 
III. Other specific types of diabetes 
A. Genetic defects of beta cell function characterized by mutations in: 
1. Hepatocyte nuclear transcription factor(HNF) 4alpha(MODY) 
2. Glucokinase(MODY 2) 
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3. HNF -1 alpha (MODY 3) 
4. Insulin promoter factor (IPF) 1 (MODY 4) 
5. HNF -1 Beta (MODY 5) 
6. Neuro D1 (MODY 6) 
7. Mitochondrial DNA 
8. Proinsulin or insulin conversion 
B. Genetic defects in insulin action: 
1. Type A insulin reistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipodystrophy syndromes 
C. Diseases of the exocrine pancreas: 
1. Pancreatitis 
2. Pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculus pancreatopathy 
D. Endocrinopathies: 
1. Acromegaly 
2. Cushing syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
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5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
E. Drug or chemical induced: 
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormone 
6. Diazoxide 
7.  Beta adrenergic agonists 
8.  Thiazides 
9.  Phenytoin 
10.  Alpha interferon 
11. Protease inhibitors 
12. Clozapine 
13. Beta blockers 
F. Infections: 
1. Congenital rubella 
2. Cytomegalovirus 
3. Coxsackie 
G. Uncommon forms of immune mediated diabetes: 
1. Stiff-man syndrome 
2. Anti insulin receptor antibodies 
 
 
14 
 
H. Other genetic syndromes sometimes associated with diabetes: 
1. Down’s syndrome 
2. Klinefelter’s syndrome 
3. Turner syndrome 
4. Wolfram’s syndrome 
5. Friedreich’s ataxia 
6. Huntington’s chorea 
7. Laurence – Moon Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader – willi syndrome 
IV. Gestational diabetes mellitus (GDM) 
Figure 4: Differentiating Type 1 and Type 2 Diabetes Mellitus 
 
15 
 
PATHOGENESIS 
NORMAL GLUCOSE HOMEOSTASIS 
The human body is dependent on a strict control of its blood glucose 
levels in order to secure normal body function24. After ingestion of mixed meal, 
50% of glucose is utilized in brain, 25% by splanchnic and gastrointestinal 
systems. Both are non-insulin dependent tissues. Only remaining 25% is taken 
by skeletal muscle and adipose tissue which are insulin dependent. 
So in a fed state there is hyperglycemia and hyperinsulinemia. This 
stimulates increased glucose uptake by muscles and decreased hepatic glucose 
production. 
Adipocytes regulate release of free fatty acids from stored triglycerides. 
They decrease the release of free fatty acids and increase glucose uptake in a fed 
state. All these effects are facilitated by insulin. It also indirectly decreases the 
glucagon secretion there by decreasing hepatic glucose production. 
Factors responsible for maintenance of normal glucose tolerance in 
healthy subjects: 
A. Insulin secretion 
B. Tissue glucose uptake 
a. Peripheral (muscle) 
b. Liver and gut (splanchnic) 
C. Suppression of hepatic glucose production 
a. Decreased FFA 
b. Decreased glucagon 
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While both type 1 and type 2 diabetes result in hyperglycemia, the 
pathophysiology and etiology of the diseases are distinct and require us to 
consider each type of diabetes independently25. 
TYPE-1 DIABETES MELLITUS 
This type of diabetes results from a severe absolute lack of insulin caused 
by reduction in beta cell mass, with preponderance for insulin dependence which 
can lead to development of serious complications such as ketoacidosis and 
coma26. 
There are three interlocking mechanisms responsible for islets cell 
destruction namely genetic susceptibility, auto immunity and environmental 
insult. 
Figure 5: Mechanism of type I diabetes 
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The major genetic susceptibility determinants are the highly polymorphic 
HLA loci on chromosome 6p21—more specifically the class II loci, HLA-DRB1,                      
HLA DQB1/DQA1 and, to a lesser extent, HLA-DPB1/DPA127. The auto 
immune reaction either develops spontaneously or triggered by environmental 
insult. 
TYPE-2 DIABETES MELLITUS 
No evidence of auto immune mechanism is involved in the pathogenesis 
of type-2 Diabetes Mellitus. Life style clearly plays a role. Genetic factors are 
even more important than in type-1 Diabetes Mellitus. It appears to result from 
multiple genetic defects or polymorphism, each contributing its own 
predisposing risk and modified by environmental factors. HLA-DQA1*0301 and 
HLA-DQA1*0501 alleles are markers of susceptibility for T2DM28.        
Figure 6: Mechanism of type II diabetes 
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Beta cell mass is decreased in obese and lean type-2 diabetes mellitus. 
The two metabolic effects that characterize type-2 diabetes mellitus are, 
1. A derangement in beta cell secretion of insulin 
2. A decreased response of peripheral tissues to respond to insulin (insulin 
resistance)29 
While much has been learned in recent years, the pathogenesis of type-2 
diabetes mellitus remains enigmatic. There is no evidence that auto immune 
mechanisms are involved. 
Among the identical twins, the concordance rate is 60% to 80%. Thus, 
identical twin pairs show a higher concordance rate for diabetes than do fraternal 
twins30. 
To summarize, type-2 diabetes mellitus is a complex, multifactorial 
disorder involving both impaired insulin release leading to relative insulin 
deficiency and end organ insensitivity. Insulin resistance frequently associated 
with obesity, produce excess stress on beta cells, which may fail in the face of 
sustained need for a state of hyperinsulinemia. Genetic reactors are definitely 
involved but how they fit into this puzzle remains mysterious. TCF7L2 is the 
strongest susceptibility locus associated with beta cell dysfunction31. 
CLINICAL FEATURES 
The symptoms of diabetes mellitus includes32 
1. Extreme tiredness 
2. Sudden weight loss 
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3. Drowsiness 
4. Dry mouth 
5. Thirst 
6. Increased hunger 
7. Increased frequency of urination 
8. Blurring of vision 
Frequent urination and increased thirst: When excess glucose builds up in 
the bloodstream, fluid is pulled from the body's tissues. Excessive thirst occurs, 
causing people with type 2 diabetes to drink and urinate more. 
Increased hunger: In type 2 diabetes the body does not have enough insulin to 
send glucose to cells. This means the muscles and organs are depleted of energy, 
resulting in increased hunger. 
Weight loss: Insufficient insulin forces the body to start burning fat and muscle 
for energy. This causes weight loss. 
Fatigue: When cells are left without enough glucose, the body becomes tired.  
Uncontrolled diabetes is associated with an increased susceptibility to 
infections and patients may present with skin sepsis (boils) and genital 
candidiasis and complain of pruritis vulvae and balanitis. 
The difference between signs and symptoms of type I and type II diabetes 
mellitus includes : 
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SIGNS & SYMPTOMS Type-1 DM Type-2 DM 
Polyuria and thirst ++ + 
Weakness and fatigue ++ + 
Polphagia with decrease in 
weight 
++ - 
Recurrent blurred vision + ++ 
Vulvovaginitis or Pruritis + ++ 
Peripheral neuropathy + ++ 
Nocturnal enuresis ++ - 
Asymptomatic - ++ 
 
The physical signs in patients with type-2 diabetes mellitus at diagnosis 
depend on the mode of presentation. More than 70% are over weight and obesity 
may be central (truncal or abdominal). Hypertension is present in 50% of patients 
with type-2 diabetes mellitus. Hyperlipidemia is also common. Sometimes 
patients present with one or more of the long term complications of diabetes 
mellitus. They may complain of parasthesia, pain and muscle weakness in the 
legs with signs of peripheral neuropathy or foot ulceration or deterioration of 
vision from cataract or retinopathy. Signs of macrovascular complications are 
common and may include diminished or impalpable pulses in the feet, bruits over 
the carotid or femoral arteries and ischaemic toes. Cutaneous features of diabetes 
include a dermopathy with trophic brownish scar on the skin and necrobiosis 
lipoidica diabeticorum. 
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Reducing hyperglcemia in patients with type-2 diabetes mellitus is done 
with antidiabetic drugs, diet and exercises that ameliorate the underlying defect 
responsible for the disease. 
From a therapeutic view the following points are pertinent: 
1. All patients with type-2 diabetes mellitus who are hyperglycemic have 
some amount of deficiency of insulin secretion. 
2. The higher the fasting plasma glucose level, the greater the degree of 
insulin deficiency. 
3. Insulin resistance is present in some patients but not in all patients with 
type-2 diabetes mellitus. 
4. The magnitude of insulin resistance varies considerably among the 
patients with type-2 diabetes mellitus and is significantly influenced by 
obesity. 
An estimate of the relative roles played by insulin resistance and insulin 
deficiency in the pathogenesis of hyperglycemia in a particular patient may be 
useful in deciding which therapeutic modalities are likely to be more effective. 
METABOLIC SYNDROME 
It describes risk factors that determine who will develop type-2 diabetes 
mellitus. They are hypertriglyceridemia, low HDL cholesterol, hypertension, 
abnormal fasting glucose level and abnormal visceral obesity. Hypertension and 
prehypertension can increase the risk of developing cardiovascular disease 
(CVD) and diabetes33. It is diagnosed by glucose tolerance test (GTT) and 
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treated with life style modifications and treatment of obesity. It prevents 
progression of impaired glucose tolerance to overt diabetes. 
                                       Figure 7: Metabolic syndrome 
 
COMPLICATIONS OF DIABETES MELLITUS34: 
ACUTE COMPLICATIONS: 
 Diabetic ketoacidosis 
 Hyperosmolar non ketotic diabetic coma 
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Figure 8: Complications of Diabetes mellitus 
 
 
CHRONIC COMPLICATIONS 
 Hypertension 
 Renal failure 
 Cataract 
 Autonomic neuropathy 
 Peripheral neuropathy 
 Myocardial infarction 
 Cerebro vascular accidents 
 Gangrene of lower extremities 
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TREATMENT OF DIABETES MELLITUS 
MODALITIES OF TREATMENT 
             Diet 
             Physical exercise 
             Insulin 
             Oral antidiabetic agents 
DIET 
             Nutrition therapy is recommended for all people with type 1 and type 2 
diabetes as an effective component of the overall treatment plan. In type 2 
diabetes mellitus, strict adherence to diet is necessary since the endogenous 
insulin reserve is limited.  
           Caloric content of the diet should be first determined according to the 
needs of the patients. Protein content should be probably 10-15% of daily 
calories. Saturated fat provide less than 10% of daily calories. Polyunsaturated 
fat provide less than or equal to 10% of daily calories. Remaining calories are to 
be divided between carbohydrates and monounsaturated fat based on medical 
needs and personnel tolerance. Dietary fibre may play a role within insulin 
sensitivity and glucose tolerance35. 
            After determining all the above mentioned factors we must decide the 
dietary substances. Initially dietary prescription for diabetic patients were rigid 
and difficult to follow. Now the concept is to provide flexibility in use of 
ordinary foods. This gives good compliance of both patients & family members. 
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Figure 9: Triangle of Diabetes management 
 
             Increasing the fiber content of the diet will be very useful. It is the long 
term overall diet pattern that count. Deviation of one or two meals does not 
matter much. 
             When the dietary modality is not adequate, we must go for oral anti-
diabetic drugs for type 2 diabetes mellitus. 
              The components of optimal medical nutrition therapy (MNT) includes 
fruits, vegetables, fibre containing foods, and low fat. MNT is a term used by the 
American Diabetes Association, it explains the coordination of caloric intake 
with other aspects of therapy. MNT is an effective and increasingly affordable 
method to prevent type 2 diabetes and to treat both type 1 and type 2 diabetes36. 
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The consumption of foods with a low glycemic index tends to reduce 
postprandial blood glucose level and improve glycemic control. Reducing 
calorie and non-nutritive sweeteners are useful. 
EXERCISE 
Regular exercise improves by37 
 Increase in the number of insulin receptors 
 Increase in the sensitivity of insulin receptors 
 Elevation of 2 to 3 DPG levels in the RBC and reduce HbA1C 
 Promote oxygen delivery to the peripheral tissues 
The benefits of exercise as identified by ADA are: 
 Improved glycemic control,  
 Enhancement of weight loss and weight maintenance 
 Prevention of cardiovascular disease 
YOGA 
The science of yoga is an ancient one. It is a rich heritage of our culture. 
The beneficial effects of yoga are: 
 Improves glycemic control 
 Elimination of stress 
 Reduction of insulin resistance 
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INSULIN 
Insulin was discovered in 1921 by Banting and Best38. It is a polypeptide 
having 51 amino acids. It contains two chains A (21 amino acids) and B (30 
amino acids). It was initially obtained from the animals as bovine and porcine 
insulin. Insulin is normally given for type 1 diabetes mellitus and some patients 
of type 2 diabetes mellitus with insulinopenia, whose hyperglycemia does not 
respond to diet therapy either alone or combined with oral anti-diabetic drugs39. 
It is injected subcutaneously several times a day into anterior abdominal wall, 
upper arms, outer thighs and buttocks.  
 Effects of insulin 
It elicits a remarkable array of biological responses. The important target 
tissues of insulin are liver, muscle and adipose tissue. The effets include 
 Decrease in blood glucose 
 Decrease in protein synthesis 
 Inhibition of breakdown of fat  
    
 
 
 
                               
                                              
28 
 
Figure 10: Effects of insulin 
 
Molecular mechanisms of insulin action 
         Insulin acts through a cell surface receptor. Insulin receptor is a ligand 
activated tyrosine kinase. When insulin binds to its receptor it leads on to rapid 
intra molecular auto phosphorylation of several tyrosine residues. The activated 
receptor kinase initiate a cascade of events by phosphorylating insulin receptor 
substrates (IRS 1-4)40. The effects of insulin receptor appear to be mediated by 
IRS -2. 
            In turn it activate other kinases including protein kinases and produce the 
physiological effects of insulin.  
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Figure 11: Mechanism of insulin 
Classification: 
1. Ultra short acting: 
               Insulin lispro 
              Insulin aspart 
              Insulin glulisine 
2. Short acting: 
              Regular insulin 
              Semi lente insulin 
3. Intermediate acting: 
              Neutral protamine Hagedorn 
              Lente insulin 
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4. Long acting: 
              Ultra lente insulin 
              Insulin glargine 
              Insulin detemir 
Insulin lispro: 
It is identical to human insulin except at positions B28 and B29 were 
proline and lysine are reversed. 
Insulin aspart: 
      It is formed by replacement of proline at the 28th position with aspartic 
acid. 
The important advantage with insulin lispro and insulin aspart is that they 
readily dissociate into monomers shortly after injection. So they can be given 
just 5 minutes before food and thereby reducing the risk of hypoglycemic attacks. 
Insulin lispro can be given in insulin pumps. 
Insulin glargine: 
Two modifications are made in human insulin. Two arginine residues are 
added to C terminus of B chain and asparginase molecule in position 21 on A 
chain is replaced with glycine. 
The advantage of this preparation is that it produces less hypoglycaemia 
and sustained peakless absorption profile. 
Conventional insulin regimen involves the administration of one or two 
injections of intermediate acting insulin with or without addition of small amount 
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of regular insulin. Multiple subcutaneous and continuous infusions are needed in 
intensive treatment schedules. The problem of hypoglycaemia is common in 
insulin dependent diabetes mellitus. Hypoglycemic attacks are dangerous and if 
frequent, leads to serious and fatal outcome. So that goal of insulin therapy is to 
keep the upper limit of postprandial blood sugar at 200 mg/dl. 
Insulin therapy: 
           In type 2 diabetes mellitus: 
Combination: 
        Use of daytime oral antidiabetic agents and single injection of intermediate 
and long acting insulin at bed time. 
Advantages: 
 Patient compliance better with single injection. 
 Less weight gain.  
 Suppress excessive hepatic glucose production at night.  
Other methods: 
 Multiple regimen: 
        Pre breakfast, pre- dinner dose of mixing intermediate and fast acting 
insulin is useful in obese type 2 diabetes mellitus patients. 
Basal Bolus Regimen: 
  There is a continuous basal insulin throughout the day with increased 
insulin at meals by bolus. Pre meal regular insulin and bed time NPH or glargine 
or Lente or ultra-Lente can be given as basal insulin. 
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 Insulin lispro or aspart can be taken 5 minutes before food as they are 
quick acting. So the risk of hyphoglycemica is less. 
 This type of intensive insulin regiments reduce microvascular 
complications. 
 Self-monitoring of blood glucose should be done by insulin treated 
patients to find out asymptomatic hypoglycaemia. But patient compliance is 
poor. 
Role of Newer Insulin: 
 Basal insulin should have a peak-less pharmacodynamic profile, at least 
24 h of duration of action, very low risk of hypoglycemia, should be tolerated 
well in both type 1 and type 2 diabetes mellitus, and should have predictable 
action without any intra and inter individual variability41.  
Inhaled Insulin 
 This newer form has recently been approved by FDA42. Patients often 
have a fear of needles and may also object to injection therapy as being 
inconvenient and unacceptable. Consequently, the pulmonary route has been 
investigated as an alternatives, less invasive method of insulin administration. 
Inhaled insulin has a faster onset of action than both insulin lispro and regular 
insulin, and its duration of action is longer than the insulin lispro and similar to 
regular insulin. These characteristics make inhaled insulin suitable for 
administration before meals to control postprandial hyperglycemia. No adverse 
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effects are reported so far. Smokers would not be able to use it because of higher 
absorption and higher incidence of hypoglycemia43. 
In comparison to animal insulin human insulin is 
 Less antigenic / less allergic reaction 
 Less insulin resistance 
 More potent 
 More hypoglycemia 
 Higher cost 
Adverse effects44:  
 Hypoglycemia 
 Insulin allergy 
 Lipodystrophy 
 Insulin resistance 
 Insulin oedema 
ORAL ANTI- DIABETIC AGENTS 
Introduction: 
 Oral anti- diabetic agents are of use in type- 2 diabetes Mellitus when it 
is not controlled by diet and exercise. These drugs can bring the blood glucose 
level back to normal in mild disease. In severe disease insulin is necessary. 
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Drugs45: 
1. Sulfonyl ureas 
2. Biguandies 
3. Meglitinides 
4. Thiazolidinediones 
5. Alpha glucosidase inhibitors 
Historical Aspects: 
 Sulfonyl ureas were discovered serendipitously in contrast to insulin 
which was discovered due to systematic investigations. In 1942 Janbon and 
colleagues noted that some sulphonamides caused hypoglycaemia in 
experimental animals. These observations were soon extended and it led to the 
development of the entire class of sulfonylureas.  
During 1920’s Biguandies were introduced but overshadowed by the 
discovery of Insulin. In 1997, the first member of a new class of oral insulin 
secretogogues called “Meglitinides” were introduced. “Thiazolidinedione’s” 
were introduced in 1997 as the second major class of insulin sensitizers. 
SULFONYL UREAS46: 
First Generation 
 Tolbutamide 
 Chlorpropamide 
 Tolazamide 
 Acetohexamide 
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Second Generation 
 Glibenclamide (Glyburide) 
 Glipizide 
 Gliclazide 
 Glimepride 
Figure 12: Structure 
 
Mechanism of Action of Sulfonyl Ureas 
Their effects in the treatment of diabetes Mellitus are more complex. 
They stimulate insulin release from the pancreatic beta cells. They reduce 
hepatic clearance of the hormones. They enhance insulin in cells and stimulate 
glucose transporters. They suppress hepatic gluconeogenesis. 
The effects of the sulfonyl ureas are initiated by binding to and blocking 
an ATP sensitive K+ channel. 
Reduced K+ Conductance causes membrane depolarization and influx of 
Ca2+ through voltage sensitive Ca2+ channels which causes insulin release. 
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Figure 13: Mechanism of sulphonylureas 
 
Pharamacokinetics of sulfonyl ureas 
 All are effectively absorbed from gastro- intestinal tract. Food and 
hyperglycemia can inhibit the absorption. So they should be ingested 30 minutes 
before food.  They are largely bound to plasma proteins especially albumin. All 
sulfonyl ureas are metabolized by the liver and metabolites are excreted by the 
kidneys. Sulfonyl ureas should be administered with caution to patients with 
either renal or hepatic insufficiency. 
Adverse Reactions of Sulfonyl ureas 
 Hypoglycemia 
 Non – Specific skin rashes 
 Nausea, Vomiting 
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 Hemolytic Anaemia 
 Agranulocytosis 
 Hepatitis 
Contraindications of Sulfonyl ureas 
 Pregnancy 
 Lactation 
 Renal Insufficiency 
 Hepatic Insufficiency 
BIGUANDIES47 
1. Metformin 
2. Phenformin 
3. Buformin 
Mechanism of Action of Biguandies 
 They are euglycemic. They enhance glucose removal from blood and 
inhibit gluconeogenesis. They are taken with or after food. They are given alone 
or with sulfonylureas. Presence of insulin is required for their action. 
 Reduce glucose production by inhibiting gluconeogenesis from liver 
 Facilitating insulin action in muscle and fat 
 Decreased glucose absorption from intestine 
 Increase insulin sensitivity (Insulin sensitizer) 
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                      Figure 14: Mechanism of Biguanide 
 
It should be used cautiously as they are prone to develop lactic acidosis. 
They are contraindicated in  
o Hypersensitivity 
o Severe pulmonary disease 
o Congestive cardiac failure  
o Recent myocardial infraction. 
Its main advantage is no weight gain. It is particularly useful in obese 
diabetic patients. It is also used for hirsuitism in women with polycystic ovary 
syndrome by reducing androgen level and increasing insulin sensitivity. 
Infertility may be treated. 
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 In type -1 Diabetes Mellitus, it is given along with insulin to decrease 
insulin resistance. 
 Phenformin and Buformin were withdrawn due to severe lactic acidosis. 
MEGLITINIDES48 
1. Repaglinide 
2. Nateglinide 
They are insulin secretogogues like sulfonyl ureas. They are useful in 
postprandial hyperglycemia exertions. They should be taken before food. 
Nateglinide with rapid onset and short duration of actions is useful for this 
purpose. Repaglinide acts by blocking ATP sensitive potassium channels in the 
beta cells of pancreas and increasing calcium influx, thus releasing insulin by 
exocytosis.  
Peak effect is observed in 1 hour of administration so if meal is delayed 
there are more chances of hypoglycaemia with repaglinide. The chances of 
hypoglycaemia with nateglinide are least among all insulin secretogogues 
including sulphonylureas49. Both the agents are metabolized by CYP3A4 and 
precaution should be taken in patients with poor hepatic function. 
THIAZOLIDINEDIONES 
It was discovered by serendipity from ciglitazone as hypolipidaemic drug 
and noticed that this drug reduced blood glucose level but it was found to be 
hepatotoxic.   
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Troglitazone was the first agent of this class and withdrawn due to severe 
hepatotoxicity, an idiosyncratic reaction.  Later on two drugs were introduced 
and they do not have hepatotoxicity. They are         
1. Pioglitazone 
2. Rosiglitazone 
They are insulin sensitizers. They need insulin for their action. They act 
through peroxisome proliferative - activated receptors gamma (PPAR-γ) they 
alter adipokinase release, increase adenopectin which enhance insulin 
sensitivity50.                                                        
                             Figure 15 : Mechanism of thiazolidinedione 
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a. Reduce insulin resistance in peripheral tissues 
b. Reduce glucose production in the liver 
c. Increased glucose transport into muscle and adipose tissues 
d. Shift fat from viscera to subcutaneous tissue 
Other effects 
a. Increases HDL 
b. Reduces TGL 
They are used as adjuvant to diet and exercises. They should be started 
with low dose. They reduce insulin requirements. They are combined with 
metformin or sulfonyl ureas. 
Adverse effects 
 Hepatotoxicity after prolonged use 
 Oedema 
 Anaemia 
 Heart failure 
 Risk of fracture in elderly (Rosiglitazone) 
Both are long acting so, once a day administration is sufficient. For fear 
of hepatotoxicity, liver function test are to be done every 6 months. It is also 
contraindicated in cardiac failure patients. Rosiglitazone has been associated 
with myocardial infarction and due to this reason it is banned in India (2010). 
The risk of bladder cancer with pioglitazone appears to be related to 
cumulative dose and duration of exposure51. 
ALPHA GLUCOSIDASE INHIBITORS 
1. Acarbose 
2. Miglitol 
3. Voglibose 
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Alpha glucosidase enzyme facilitates digestion of oligosaccharides and 
disaccharides into monosaccharides, thus it is absorbed from the small intestine. 
Acarbose was the first agent of this class. They act by inhibiting alpha 
glucosidase at brush border of intestine and thereby decreasing absorption of 
sugars. So they should be taken just before each meal. The enzymes 
glucoamylase and sucrase are also inhibited52. 
Regular use tends to lower HbA1C. It can be used as monotherapy in the 
elderly patients or in a patient having mainly postprandial hyperglycemia. They 
are combined with insulin or sulfonyl ureas. 
Figure 16 : Mechanism of alpha glucosidase inhibitors 
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Adverse effects 
 Flatulence 
 Diarrhoea 
 Abdominal pain 
Precaution should be taken while treating hypoglycaemia who are taking 
other hypoglycaemic agents with acarbose. It should be corrected by giving 
glucose and not by sucrose, because its breakdown is already blocked.  
Contraindications 
 Inflammatory bowel disease 
 Intestinal obstruction 
NEWER DRUGS 
Incretin - mimetic 
1. Exenatide 
2. Liraglutide 
3. Albiglutide 
4. Dulaglutide  
Dipeptidyl peptidase 4 inhibitors 
1. Sitagliptin 
2. Vildagliptin 
3. Saxagliptin  
4. Linagliptin 
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Amylin analogue 
1. Pramlintide 
 
Sodium glucose cotransporter 2 (SGLT-2) inhibitors 
1. Canagliflozin  
2. Dapaglifozin 
3. Serglifozin 
4. Empagliflozin   
 
Other hypoglycaemic drugs 
1. Colesevelam hydrochloride 
2. Bromocriptine 
  
Exenatide 
       It is a synthetic analogue of glucagon like peptide 1 (GLP-1). It is the first 
incretin therapy to become available for the treatment of Diabetes mellitus. It is 
orally inactive, hence approved as an injectable (subcutaneous) and can be used 
as an adjuvant therapy in individuals with type 2 Diabetes mellitus treated with 
metformin or sulphonyl ureas who still have suboptimal glycaemic control53.                           
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Figure 17 :  Mechanism of GLP-1 analogue 
 
 Stimulates insulin secretion from beta cells of pancreas 
 Slows the rate of nutrient absorption by slowing gastric emptying 
 Decrease appetite by acting at hypothalamus 
 Decrease glucagon release 
 Lowers HbA1C level 
 Reduces the risk of heart disease              
Exenatide and liraglutide must be administered subcutaneously. 
Liraglutide is highly protein bound and has a long half life, allowing for once 
daily dosing. Exenatide is absorbed orally from arm, abdomen and thigh, 
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reaching peak concentration in approximately 2 hours with a duration upto 10 
hours. It is injected within 60 minutes before a meal. 
Adverse effects 
 Nausea 
 Anorexia 
 Diarrhoea 
 Necrotising and hemorrhagic pancreatitis  
Disadvantages  
 Expensive 
 Parenteral preparation (s.c) 
 Risk of hypoglycemia 
Sitagliptin and Vildagliptin 
          Both are orally active selective inhibitor of dipeptidyl –peptidase 4 (DPP-
4)54, the enzyme that degrades incretin and other GLP-1 like molecules. As a 
result GLP-1 levels are increased and its actions are prolonged. Efficacy is linked 
with endogenous GLP-1. These have longer plasma half life. It is approved for 
use in type 2 Diabetes mellitus and used as an adjuvant in combination with 
sulphonylureas or metformin.  
Adverse effects 
 Gastrointestinal side effects 
 Nasopharyngitis  
 Upper respiratory tract infection 
 Allergy 
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Pramlintide55 
It is a soluble injectable synthetic analogue of amylin that modulates 
postprandial glucose levels. It is approved for pre-prandial use in individuals 
with type 1 and type 2 diabetes mellitus.   
Figure 18 : Structure of pramlintide 
 
It is administered in addition to insulin in those who are unable to achieve 
their target post-prandial blood glucose levels. It suppresses glucagon release via 
undetermined mechanisms, delays gastric emptying and has central nervous 
system mediated anorectic effects. It is rapidly absorbed after subcutaneous 
administration. Peak levels within 20 minutes and the duration of action is not 
more than 150 minutes. It is renally metabolized and excreted even with low 
creatinine clearance. It has not been evaluated in dialysis patients. The most 
reliable absorption is from the abdomen and thigh. It should be injected 
immediately before eating. Doses range from 15mcg to 120mcg. Therapy should 
be initiated with the lowest dose and titrated upwards. It should always be 
injected separately and it should not be mixed with insulin. 
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Adverse effects 
 Gastrointestinal side effects 
 Hypoglycaemia  
Sodium glucose cotransporter -2 inhibitors (SGLT-2) 
         Dapaglifozin, serglifozin and remoglifozin are newer antidiabetic drugs 
that have successfully cleared phase 3 trials. The kidney continuously filters 
glucose through glomerulus and this glucose is reabsorbed back from the 
proximal tubule by a transporter called SGLT-2.  
        These drugs act by inhibiting SGLT-2, decreases the amount of glucose 
absorption from the proximal tubule and increases its excretion in urine56.  
Advantages 
 Weight loss 
 No hypoglycaemia (not inducing insulin secretion) 
 Improve insulin resistance  
 Beneficial in patients of DM with hypertension because of their diuretic 
effects. 
Disadvantages 
 More polydipsia 
 Increased risk of urinary bacterial/fungal infection  
 Risk of sodium loss 
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THE GOALS OF THERAPY57 
With all these modalities, the aim of treatment is to achieve almost near 
normal glucose metabolism. By keeping the body weight and blood glucose 
concentration at ideal level, metabolic profile is improved. This helps to lower 
the incidence of vascular disease and specific diabetic complications. 
          For both type 1 and type 2 diabetes mellitus, the goals are to  
 Eliminate symptoms due to hyperglycaemia 
 Reduce the long term complications of DM 
 To achieve  as normal a lifestyle as possible 
 
Figure 19: Modalities of treatment 
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Treatment goals for adults with Diabetes 
HbA1C <7.0% 
Preprandial capillary plasma glucose 80-130mg/dl 
Postprandial capillary plasma glucose <180mg/dl 
 
Drawbacks of oral antidiabetic drugs 
They are ineffective in 20% of newly diagnosed patients of type 2 
diabetes mellitus and in some patients the initial response decreases after several 
years. 
Their use is complicated due to hypoglycaemic attacks and significant 
drug interactions. The use of OHA produce unwanted side effects58. They should 
be used cautiously in patients with liver diseases particularly biguanides and 
thiazolidinediones. 
Figure 20 : Drawbacks of oral antidiabetic agents 
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So search still continues for better hypoglycaemic agents. 
 None of them (OHA) can maintain blood glucose level within normal 
limits around the clock. 
 In large doses they pose the problem of hypoglycaemia 
 Often insulin resistance may complicate the disease management 
 Lactic acidosis is seen with biguanides 
 Vitamin B12 and folate deficiency 
 Gastrointestinal disturbances  
 Altered liver function test 
On account of the above limitations of modern drug therapy in the 
treatment of diabetes, there is a switch over to old remedies, which have the 
healing powers. They include the use of plants and other natural products which 
are capable of alleviating diabetes mellitus. It has emerged as the recent trend 
world over. 
PLANT DERIVED DRUGS 
Medicinal substances of plant origin are known to mankind for several 
centuries. Majority of medicines were formulated from herbs until the previous 
century. Current day pharmaceutical industry still depends on plant sources for 
the synthesis of many lead compounds as a vital part in new drug development. 
Plant derived drugs are called phytomedicines. 
According to World Health Organization (WHO), more than 10,000 plant 
species are in use worldwide. 20 -50% of patients consume herbal medicines. 
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They are taken either as a whole or its components, extracts, tablets, capsules, 
syrups. 
India is known for its medicinal plants. Thousands of medicinal plants 
have been identified. These include herbal, medicinal and aromatic plants. India 
has indigenous medical systems like ayurveda, siddha and unani medicine where 
herbal medicines are mainly used.  
Traditional medicine is being integrated worldwide along with the 
primary health care because of its easy accessibility to all and acceptability. 
Medicines used in alternative therapies are not approved drugs with proven 
safety, efficacy and quality. These medicines are having traditional values and 
are used empirically.  
 Mostly female patients with chronic medical problems seem to choose 
herbal medicines. Diabetes mellitus, sleep disorders, obesity, benign prostatic 
hypertrophy, chronic pain, erectile dysfunction, common cold, cough, cancer, 
HIV, arthritis are some of the diseases where herbal medicines are commonly 
used. 
Herbal medicines are widely used because of easy availability and the 
belief that ‘naturalness’ of the phytomedicines always protects rather than cause 
adverse effects. Due to lack of regulation regarding their production, they are 
prone to cause adverse effects due to contaminants and adulterants. Since no 
medicine is free from side effects, herbal medicines must also be subjected to 
proper clinical trial.  
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ALOE VERA 
Figure 21: Aloe Vera 
 
In traditional medicines, aloe vera has been used either alone or along 
with other herbal remedies for the treatment of Diabetes mellitus.  
ALOE VERA  
Aloe vera locally known as kawar gandal and it is a cactus-like plant with 
green, dagger-shaped leaves. The name was derived from the Arabic 'alloeh' 
meaning 'bitter'59, because of the bitter liquid found in the leaves. It is also known 
as 'lily of the desert' 
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Aloe vera is a plant species of the genus Aloe. It grows wild in tropical 
climates around the world and is cultivated for agricultural and medicinal uses. 
It grows successfully indoors as a potted plant. 
It is found in many consumer products including beverages, skin lotion, 
cosmetics, or ointments for minor burns and sunburns. There is trivial scientific 
evidence of the effectiveness or safety of Aloe vera extracts for either cosmetic 
or medicinal purposes.  
The plant 
Aloe vera is a very short-stemmed plant growing to 60–100 cm tall, 
spreading by offsets. The leaves are thick, fleshy and it looks green to grey-
green. Some varieties showing white flecks on their upper and lower stem 
surfaces. The margin of the leaf is serrated and has small white teeth. 
Figure 22 : Scientific classification of Aloe vera 
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Parts used 
Aloe vera gel  
Distribution 
The species has been widely cultivated around the world. It was 
introduced to China and various parts of southern Europe in the 17th century and 
it is widely naturalized elsewhere, occurring in temperate and tropical regions of 
Australia, South America, Mexico, the Caribbean and southeastern United states.                  
SYNONYMS60 
1. Aloe barbadensis Mill 
2. Aloe barbadensis var. Chinensis Haw 
3. Aloe chinensis Baker 
4. Aloe elongata Murray 
5. Aloe flava pers 
6. Aloe indica Royle 
7. Aloe lonzae Tod 
8. Aloe maculata forssk 
9. Aloe perfoliata var 
10. Aloe rubescens DC 
11. Aloe variegata forssk 
12. Aloe vera Mill 
13. Aloe vera var lanzae Baker 
14. Aloe vera var chinensis 
15. Aloe vulgaris Lam 
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Aloe vera leaves contain phytochemicals such as acetylated mannans, 
polymannans, anthraquinone C-glycosides, anthrones, other anthraquinones, 
such as emodin, lectins. It also consists of D-glucose and D-mannose, tannins, 
steroid, enzymes, plant hormones, amino acids, vitamins and minerals. This may 
be responsible for their bioactivity.                                      
Figure 23 : Aloe vera- The miracle plant 
 
Health benefits 
Aloe vera is a rich source of antioxidants which inhibits the growth of 
infection spreading bacteria.  
 increases collagen production  
 improves skin elasticity   
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 keeps the skin hydrated   
 reducing acne and premature ageing.  
Topical Aloe vera gel is supposed to be quite effective against burns in 
particular. 
Aloe vera is packed with all the vitamins and minerals (Vitamins – A, C, 
E, B1, B2, B3, B6, B12, folic acid, calcium, magnesium, zinc, iron and more)  for 
shiny healthy hair. It has a chemical makeup similar to that of keratin, and it 
rejuvenates the hair with its own nutrients, giving it more elasticity and 
preventing breakage. 
The latex (sticky yellow residue found just under the skin of the leaf) in 
aloe vera is considered to have strong laxative effects, which helps to relieve 
constipation. The cooling effects of aloe vera benefit patients with problems of 
acidity. 
It also detoxifies the stomach, curing indigestion, gas and curbs the 
growth of unhealthy bacterial growth. It is also a 
 Good protector of the liver  
 Promotes blood circulation 
 Combats cholesterol and diabetes  
 Improves cellular oxygenation. 
Dose 
In capsule, it is recommended to take 200-300mg/day. For the juice, 2-3 
table spoons (50ml) per day is recommended. 
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Aloe vera combinations 
Aloe vera can combine with  
 Spirulina and Chlorella for the detoxification of the organs  
 Acai Berry and Goji Berry for the protection of eyes, skin, hair and nail  
 Ginkgo Biloba for protection from radiation 
 Ginger and turmeric to prevent from cancer, gastrointestinal problems. 
ANIMAL MODEL OF EXPERIMENTAL DIABETES MELLITUS 
In the 1980’s von Mering was working on the absorption of fat from the 
intestine after removing the pancreas of a dog. The animal developed polyuria, 
polydipsia and was found to have diabetes mellitus. Many experiments on rabbits 
and dogs followed, although history has given a special place to Marjorie, one 
of the dogs used by Banting and Best in their seminal experiments on the 
isolation and purification of insulin in the 1920’s.  
There are many animal models which include: 
1. Models for insulin dependent diabetes mellitus (IDDM) 
2. Models for non insulin dependent diabetes mellitus (NIDDM) 
3. Transgenic and knockout animals 
4. Invitro methods on isolated organs, cells and membranes 
5. Models to study insulin secretion from beta cells 
6. Experimental models for diabetic complications  
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METHODS OF INDUCING DIABETES MELLITUS IN ANIMALS61 
1. Models for IDDM 
 Chemical induced 
 Virus induced 
 Hormone induced 
 Insulin antibodies induced 
 Surgical - Pancreatectomy 
 Transgenic animals 
 Chemical induced 
Streptozotocin and Alloxan are widely used to induce experimental 
Diabetes Mellitus in animals but the mechanism of production of Diabetes 
Mellitus are different in each.   
Virus induced 
Various human viruses used for inducing diabetes include RNA 
picornoviruses, coxsackie-B4, reovirus, mengo-2T and lymphocytic 
choriomeningitis virus. Viruses may produce diabetes mellitus by infecting and 
destroying of beta cells in pancreas. 
Hormone induced 
Dexamethasone, a long acting glucocorticoid is used to produce diabetes 
mellitus. Corticotropin is used to stimulate adrenal cortex that results in 
hormonal imbalance causing steroid diabetes. 
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Insulin antibodies induced diabetes: 
Giving bovine insulin along with CFA to guinea pigs produce anti-insulin 
antibodies. Intravenous injection of 0.25 ml-1.0 ml guinea pig anti-insulin serum 
to rats induce a dose dependent increase in blood gluose levels upto 300 mg/dl.   
Surgical induced 
In partial pancreactectomy, more than 90 % of the organ must be removed 
to produce diabetes and total removal of the pancreas results in an insulin 
dependent form of diabetes. It results in loss of alpha and delta cells in addition 
to beta cells. This causes loss of counter regulatory hormones, glucagon and 
somatostatin.  
Genetic models 
• The NOD mouse 
• The BB rat 
• WBN/KOB rat 
• Cohen diabetic rat 
Others 
 Monogenic models in obesity and NIDDM 
 Polygenic models in obesity and NIDDM 
 Transgenic and knockout techniques 
Among the chemical methods ‘STREPTOZOTOCIN’ (STZ) induced 
diabetes is undertaken in this study. 
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STZ (2-deoxy-2-(3-methyl-3-nitrosourea) 1-D-glucopyranose) is a broad 
spectrum antibiotic, which is produced from Streptomyces achromogens. 
Rakieten et al. first described the diabetogenic property of STZ.  
Mechanism of causing beta cell damage by STZ: 
• By process of methylation 
• Free radical generation 
• Nitric oxide generation 
STZ induced diabetes in almost all species of animals. Diabetogenic doses 
varies with species and the optimal dose required in rats are 50-60mg/kg 
intraperitoneally. The blood glucose level shows the triphasic response with 
hyperglycemia at 1 hour, followed by hypoglycemia, which lasts for 6 hrs and 
stable hyperglycemia by 24-48 hrs.    
Multiple low dose of STZ also induce diabetes by causing immune 
mediated pancreatic insulitis in rats. Cyclosporin-A when given with STZ 
enhances its diabetogenic efficacy. STZ combined with complete Freund’s 
adjuvant: each of CFA, incomplete Freund’s adjuvant, Mycobacterium 
butyricum (component of CFA), Listeria monocytogens, or endotoxin 
administered 24 hours prior to STZ and then repeated in the three subsequent 
weeks, all produce hyperglycemia. Neither four administration of CFA nor of 
STZ alone result in persistent hyperglycemia.  
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Advantages and disadvantages 
STZ has almost completely replaced alloxan for inducing diabetes 
because of 
• Greater selectivity towards beta cells 
• Lower mortality rate 
• Longer or irreversible diabetes induction 
• However, guinea pigs and rabbits are resistant to its diabetogenic action. 
The following factors have been considered as possible causes of the 
selective destruction of beta cells of diabetogenic agents: 
 Low concentration of a critical enzyme or co-enzyme (possibly 
glutathione) in the beta cell. 
 Low concentration of an anti-diabetogenic or protective substance 
(glutathione) in the beta cell. 
 Inability or diminished ability of the beta cell to destroy or to detoxify 
diabetogenic agents. 
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MATERIALS AND METHODS 
           In the present study, the antihyperglycemic activity of aloevera gel was 
evaluated in adult male albino rats.  
          The study was done in the central animal house, Institute of Pharmacology, 
Madurai Medical College, Madurai after getting approval by Institutional 
Animal Ethical Committee of Madurai Medical College, Madurai, dated 
23.03.2017. 
STUDY CENTER 
Institute of Pharmacology, 
Madurai Medical College, Madurai 
DURATION OF THE STUDY 
This study was done for a period of 6 months since January 2017. 
NUMBER OF ANIMALS USED 
24 adult male albino rats weighing about 150 –200 grams 
Materials used for the study 
1. Male Albino rats (Twenty four) 
2. Streptozotocin 
3. Tab Glibenclamide 
4. Aloe vera gel extract 
5. Glucometer  
6. Glucose strips 
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7. Oral feeding tube  
8. Syringes. 
ANIMALS 
Inbred adult male albino rats from central animal house, Madurai Medical 
College were utilized in this study. 24 male albino rats each weighing 150 to 200 
grams were included in the study. Animals were allowed standard diet (pellet 
feed) and tap water ad libitum. 
Each group of animals were housed separately with a distinct identity for 
each animal throughout the study. The diabetic rats were given special care. The 
floor of cages were filled with thick layer of saw dust and it was changed daily. 
The diabetic rats were given adequate food pellets and plenty of water by 
providing two water bottles as the diabetic rats will have polyphagia, polyuria 
and polydipsia. The bottles were filled with fresh tap water every morning. 
STREPTOZOTOCIN 
Streptozotocin manufactured by Sisco Research Laboratories Pvt. Ltd 
was used  to induce diabetes mellitus in the albino rats.  Streptozotocin was given 
at the dose of 60mg/kg intraperitoneally as a single dose after overnight fasting.  
GLIBENCLAMIDE 
        Glibenclamide manufactured by Aventis pharma limited (Trade name- 
Daonil) was used as the standard sulphonyl urea. It is available as 5 mg tablet 
and the rats were given 1 mg/kg per day orally.   
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COLLECTION OF BLOOD SAMPLES 
           The rats were kept in the restrainer. Lateral veins were located and xylol 
was applied to make the vein prominent. After disinfecting with spirit, 0.2 ml of 
blood was collected using a 22 gauge needle. 
METHOD OF GLUCOSE ESTIMATION 
Blood sugar was estimated using glucometer. It uses the glucose oxidize 
enzyme specific sticks. This method is very reliable, easy and quick to perform. 
The blood sample was directly placed on the test strip kept in the glucometer. 
The results will appear in the screen in 15 seconds. 
 
EXTRACTION PROCEDURE 
ALOE VERA GEL EXTRACT 
The plant was obtained from local areas in Madurai and the species was 
identified and authenticated by Dr. Stephen, taxonomist, of American College, 
Madurai and further processing was done by Pharmacognosy department, 
Madurai Medical College. 
Fresh succulent leaves of aloe vera were collected, the inner gel 
component removed and the leafy exudate homogenized in an electric blender. 
This was subsequently lyophilized and stored at 4°C. The extract was weighed 
and reconstituted daily, with distilled water according to the dosage needed 
(200mg/kg & 400mg/kg) and administered orally, for a period of 14 days. 
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         Glibenclamide was dissolved in distilled water and given in the dose of 1 
mg/kg. The standard drug as well as the test extracts of aloe vera gel were given 
orally using oral feeding tube.  
ORAL FEEDING TECHNIQUE 
16 Guage feeding tube about 2-3 inches in length which is blunted at the 
tip with a small ball soldered around the tip was used. The needle was attached 
to 1 ml syringe containing the drug to be administered. Each rat was grasped 
gently and secured by the nape of the neck, holding the whole animal with the 
left hand.  After introducing the oral feeding tube laterally through the interdental 
space, it was advanced into the oesophagus with a gentle rotatory movement. 
Once it reached the desired level the drug was gently pushed inside. 
METHODOLOGY 
The study followed the principles of CPCSEA and utmost care was taken 
while handling the animals and adequate care was provided to them during and 
after experimentation.  
        All the twenty four male albino rats selected were starved for 18 hours. 
Fasting blood glucose level was noted for all the rats by tail venepuncture 
method. Animals were given feed and water ad libitum. Post prandial blood 
glucose level for all the rats were screened and found to be within normal limits. 
Hypoglycemic effect of aloe vera gel extract in normal rats 
         Initially 18 animals were selected from the screened group and divided into 
3 groups of 6 each. Fasting blood glucose was estimated. The first group received 
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pellet diet and served as control. Second and third groups received aloe vera gel 
extract in the dose of 200 and 400 mg/kg respectively. Blood glucose levels of 
all the three groups were estimated on 1st day, 7th day and 14th day. The results 
were tabulated. 
Hypoglycemic effect of aloe vera gel extract in diabetic rats: 
After a washout period of 1 month, all the rats were induced diabetes with 
Streptozotocin given at a dose of 60 mg/kg intraperitoneally as a single dose after 
18 hours of fasting. 72 hours after Streptozotocin administration, the diabetic 
state was confirmed by blood glucose estimation for all the animals. 
       The diabetic rats were divided into four groups of six animals each. The 
first group received pellet diet and water served as control group. The second 
group received the standard drug Glibenclamide at the dose of 1 mg/kg/day per 
oral. Third and fourth groups received aloe vera gel extract in the dose of 200 
and 400 mg/kg respectively served as Test 1 and Test 2 groups.    
GROUP STUDY TREATMENT 
I CONTROL Normal feed and water ad libitum 
II STANDARD Normal feed and water +Tab Glibenclamide (1 mg/kg) oral 
III TEST -1 Normal feed and water + Aloe vera gel extract (200 mg/kg) oral 
IV TEST -2 Normal feed and water + Aloe vera gel extract (400 mg/kg) oral 
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The blood glucose level were estimated on 1st day, 7th day and 14th day 
and the results are tabulated. The data were analysed by using students 
unpaired‘t’ test to assess the level of significance. 
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RESULTS 
In the present study 24 albino rats were selected and evaluated the 
antihyperglycemic effect of aloe vera gel extract in normal and streptozotocin 
induced diabetic rats.  
NON - DIABETIC RATS 
              Initially 18 animals with normal fasting and postprandial blood glucose 
were selected and divided into 3 groups, control, test 1 and test 2. The first group 
received pellet diet and served as control. The second and the third groups 
received aloe vera gel extract in the dose of 200 and 400 mg/kg respectively. The 
blood glucose levels in non-diabetic rats of all the three groups on day 1 were 
                The blood glucose levels in non-diabetic rats in mg/dl on day 1 
S No Control AV-200mg/kg AV-400mg/kg 
1 96 94 102 
2 102 104 94 
3 104 98 87 
4 96 104 95 
5 102 97 103 
6 84 87 96 
 
There was no significant reduction in blood glucose in the aloe vera 
treated group when compared with control. 
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The graph showing blood glucose levels in non-diabetic rats of all the 
three groups on day 1 were: 
 
The first group received pellet diet and served as control. In addition to 
normal pellet diet, the second and the third groups received aloe vera gel extract 
in the dose of 200 and 400 mg/kg respectively. The blood glucose levels in non-
diabetic rats of all the three groups on day 7 were 
       The blood glucose levels in non-diabetic rats in mg/dl on day 7  
S No Control AV-200mg/kg AV-400mg/kg 
1 106 108 98 
2 98 96 96 
3 84 96 94 
4 103 98 86 
5 98 103 97 
6 92 93 86 
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The graph showing blood glucose levels in non-diabetic rats of all the 
three groups on day 7 were: 
 
The blood glucose levels in non-diabetic rats of all the three groups on 
day 14 were: 
The blood glucose levels in non-diabetic rats in mg/dl on day 14 
S No Control AV-200mg/kg AV-400mg/kg 
1 103 96 96 
2 98 102 103 
3 92 103 97 
4 104 88 102 
5 96 96 86 
6 103 102 84 
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The graph showing blood glucose levels in non-diabetic rats of all the 
three groups on day 14 were: 
 
Control Group 
           The mean blood glucose values of rats on normal pellet diet (non-diabetic 
rats) on day 1, day 7 and  day 14 were 96± 0.1, 96.8± 7.9 and 99.3± 5.2 
respectively as shown in Table No.1 (p > 0.1). 
Test group 1 (Aloe Vera gel extract 200mg/dl) 
             The mean blood glucose values of rats after administering Aloe vera gel 
extract of 200mg/kg on day 1, day 7 and day 14 were 97.3± 6.4, 99± 5.5 and            
97.3± 5.7 respectively as shown in Table No.1 (p > 0.1). 
Test group 2 (Aloe Vera gel extract 400mg/dl) 
              The mean blood glucose values of rats after administering Aloe vera gel 
extract of 400mg/kg on day 1, day 7 and day 14 were 96.1± 5.8, 92.8± 5.4 and 
94.6± 7.9 respectively as shown in table No.1 (p > 0.1).        
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Table -1 
Mean blood Glucose Levels in Non-Diabetic Rats in mg/dl 
Group Day 1 Day 7 Day 14 
Control 
Normal pellet diet 
96±0.1 96.8±7.9 99.3±5.2 
Test 1 
AV gel extract 200 
mg/dl 
97.3±6.4 99±5.5 97.3±5.7 
Test 2 
AV gel extract 
400 mg/dl 
96.1±5.8 92.8±5.4 94.6±7.9 
 
(P > 0.1) 
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The graph showing mean blood glucose levels in non-diabetic rats in mg/dl 
   
            
It was noted that from the above data, aloe vera gel extract has no 
hypoglycemic effect in normal rats. (non-diabetic rats). 
 
DIABETIC RATS 
Diabetes was induced in all the rats by administering streptozotocin 
intraperitoneally in a dose of 60mg/kg. All the animals were found to be diabetic 
after 72 hours. The blood glucose values more than 250 mg/dl was considered as 
as diabetes. The animals were divided into four groups of six animals each. They 
are control, standard, test 1 and test 2.  
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The blood glucose levels in diabetic rats in mg/dl on day 1 
S No Control Standard AV-200mg/kg AV-400mg/kg
1 253 116 242 240 
2 257 108 248 246 
3 260 112 251 250 
4 254 107 247 246 
5 262 114 245 244 
6 260 109 253 251 
 
The graph showing blood glucose levels in diabetic rats of all the three 
groups on day 1 were:  
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The first group received pellet diet and served as control. The standard 
group received Tab Glibenclamide. The third and fourth groups received aloe 
vera gel extract in the dose of 200 and 400 mg/kg respectively. The blood glucose 
levels in diabetic rats of all the three groups on day 7 were 
The blood glucose levels in diabetic rats in mg/dl on day 7 
S No Control Standard (Glibenclamide) AV-200mg/kg 
AV-
400mg/kg 
1 267 97 184 169 
2 265 92 178 172 
3 264 94 182 170 
4 262 88 180 168 
5 267 92 183 173 
6 265 87 179 176 
 
The graph showing blood glucose levels in diabetic rats in all the three groups 
on day 7 were  
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The control group received pellet diet and the standard group received 
Tab Glibenclamide. The third and fourth groups received aloe vera gel extract in 
the dose of 200 and 400 mg/kg respectively. The blood glucose levels in diabetic 
rats of all the three groups on day 14 were 
The blood glucose levels in diabetic rats in mg/dl on day 14 
S No Control Standard AV-200mg/kg AV-400mg/kg 
1 262 76 169 162 
2 266 68 172 166 
3 262 78 174 160 
4 268 75 167 159 
5 265 67 177 166 
6 270 77 178 158 
 
The graph showing blood glucose levels in diabetic rats of all the three groups 
on day 14 were 
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Control Group 
The mean blood glucose values of rats on normal pellet diet (Diabetic 
rats) on day 1, day 7 and day 14 were 257.6± 3.6, 265± 1.8 and 265.5± 3.2 
respectively as shown in Table No.2 
Standard group 
          The mean blood glucose values after the administration of Glibenclamide 
on day 1, day 7 and day 14 were 111± 3.5, 91.6± 3.7 and 73.5± 4.7 respectively 
as shown in Table No.2.  
           Statistical analysis by student’s unpaired ‘T’ test revealed the 
antihyperglycemic effect of standard drug (Glibenclamide) is highly significant 
when compared with control group (p < 0.005). 
Test Group 1 (Aloe Vera gel extract 200mg/dl) 
             The mean blood glucose values of rats after administering Aloe vera gel 
extract of 200mg/kg on day 1, day 7 and day 14 were 247.6± 3.9, 181± 2.3, 172± 
4.3 respectively as shown in Table No.2.  
             The aloe vera gel extract of 200mg/kg has shown significant 
antihyperglycemic effect when compared with control group (p < 0.05). 
Test Group 2 (Aloe Vera gel extract 400mg/dl) 
              The mean blood glucose values of rats after administering Aloe vera gel 
extract of 400mg/kg on day 1, day 7 and day 14 were 246.1± 4.1, 171.3± 2.9,       
162.8± 3.2 respectively as shown in Table No.2. 
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Table -2 
Blood Glucose Levels in Diabetic Rats in mg/dl 
Group Day 1 Day 7 Day 14 
Control 
Normal pellet diet 
257.6±3.6 265±1.8 265.5±3.2 
Standard - 
Glibenclamide 
111±3.5** 91.6±3.7** 73.5±4.7** 
Test 1 
AV gel extract 
200 mg/dl 
247.6±3.9 181±2.3 172±4.3 
Test 2 
AV gel extract 
400 mg/dl 
246.1±4.1* 171.3±2.9* 162.8±3.2* 
 
*p < 0.05 
**p < 0.001 
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The aloe vera gel extract of 400mg/kg has shown significant 
antihyperglycemic effect when compared with control group (p < 0.05). 
 
Percentage fall in blood glucose values in diabetic rats 
              The percentage fall in blood glucose values in the various groups of 
diabetic rats was shown in Table 3. The percentage of fall in blood glucose levels 
with standard Glibenclamide in an average was 64.1% and with the aloe vera gel 
400mg/kg treated group was 24.6% when compared with control group                                  
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Table -3 
Percentage Fall in Blood Glucose values in Diabetic Rats 
Groups Day 1 Day 7 Day 14 Average 
Standard - 
Glibenclamide 
56.8% 64.3% 71.4% 64.1% 
Test 1 
AV gel extract 200 
mg/kg 
3.8% 29.7% 32.8% 22.1% 
Test 2 
AV gel extract 
400 mg/kg 
4.4% 32.3% 37.1% 24.6% 
 
The graph showing percentage fall in blood glucose values in Diabetic Rats: 
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DISCUSSION 
Diabetes mellitus is a chronic debilitating metabolic disorder charaterised 
by hyperglycemia and at present, there is a steep rise in the prevalence of DM. It 
is the major cause of morbidity and mortality worldwide as it may lead to health 
complications and affect quality of life62. 
Basically, the management of diabetes initiates with a diet modification 
and exercise. Nonetheless, most diabetic patients eventually require 
pharmacotherapy, such as oral antidiabetic drugs or injection of insulin. These 
synthetic drugs are the mainstay of treatment of diabetes and are effective in 
controlling hyperglycemia but they are not free from harmful side effects. 
The limitations, side-effects, and cost of the currently available oral anti-
diabetic agents to control blood glucose have stimulated and sparked the 
researchers to discover and develop novel anti-diabetic agents with fewer side-
effects and potential therapeutic outcomes63. 
As an alternative mode of treatment, Ayurvedic medicine has been 
claimed to be more efficacious and less toxic64. An investigation of 
antihyperglycemic agents of plant origin used in traditional medicine seems 
important as per the recommendations of World Health Organization (WHO) 
Expert committee on diabetes mellitus. 
Medicinal plants having beneficial effects on diabetes have been reported 
on several ethnopharmacologial studies. The hypoglycaemic activity of a huge 
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number of medicinal plants used traditionally has been evaluated and confirmed 
in different animal models65. 
Emblica officianalis (India gooseberry or amla), Green tea (Camelia 
sinensis), Momordica Charantia (Bitter guard), Cinnamon bark are proved to be 
effective antihyperglycemic agents acting through various mechanisms66. In this 
study, one such herbal remedy Aloe Vera gel was evaluated for its 
antihyperglycemic effect in normal adult male albino rats and Streptozotocin 
induced diabetic rats. 
Initially, antihyperglycemic effect of aloe vera gel extract was evaluated 
in normal (non-diabetic) adult male albino rats. Three groups of six each includes 
control, test 1 and test 2 respectively. The blood glucose levels in non-diabetic 
rats of both the test groups of aloe vera gel extract 200mg/kg and 400mg/kg on 
day 1, day 7 and day 14 was not much reduced when compared with control 
group (p > 0.1). It is noted that from the above data, aloe vera gel extract did not 
produce the  hypoglycemic effect in normal rats. 
After the washout period of one month, antihyperglycemic effect of aloe 
vera gel extract was evaluated in Streptozotocin induced diabetic rats. Four 
groups of six each included control, standard, test 1 and test 2 respectively. 
On day 1, when compared with the control group, there was an immediate 
fall in blood glucose level in the standard Glibenclamide group (111 ±3.5) but      
could not see the immediate fall with the test groups. Later, on day 7 and day 14 
there was a significant fall in blood glucose level in the aloe vera gel treated 
groups. 
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Statistical analysis by student’s unpaired‘t’ test revealed that the 
antihyperglycemic effect of standard drug (Glibenclamide) was highly 
significant when compared with control group (p < 0.001). 
The aloe vera gel extract of 200mg/kg and 400mg/kg has shown 
significant antihyperglycemic effect when compared with control group (p < 
0.05). 
The percentage fall in blood glucose levels with standard Glibenclamide  
was 64.1% and with the aloe vera gel 400mg/kg treated group was 24.6% when 
compared with control group. 
Like many chronic disease, chronic hyperglycemia is presumed to cause 
elevated concentrations of reactive oxygen species and lowered enzymatic as 
well as nonenzymatic cell antioxidant defences. Reactive oxygen species have 
been suggested to be involved in beta cell dysfunction and insulin resistance67. 
As explained in an in vitro study of the radio protective efficacy of Aloe vera gel, 
it is able to scavenge the free radicals 2,2-diphenyl-1-picrylhydrazyl (DPPH), 
2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid), and nitric oxide in a 
concentration-dependent manner68. 
Jain et al found that Aloe vera gel has significant antidiabetic and 
cardioprotective activity as it significantly reduced oxidative stress in 
streptozotocin induced diabetic rats and improved antioxidant status. 
Previous studies focus on the phytocomponents present in the aloe gel 
having various biological properties that help to improve health and prevent 
85 
 
disease conditions. An inner clear gel of aloe vera contains 99% water and rest 
is made of glucomannans, amino acids, lipids, sterols, vitamins, enzymes, 
minerals, saponins and lignin. It contains 75 potentially active constituents and 
natural antioxidants (total phenols, total flavonoid, vitamin A (beta-carotene), 
vitamins C (ascorbic acid) and vitamin E (tocopherol) which are responsible for 
the antioxidative effect of this plant69. It also contains vitamin B12, folic acid, 
and choline. 
In vivo and in vitro studies strongly demonstrate that the water soluble 
fraction of Aloe vera and some of its components modulate glucose transporter-
4 mRNA expression thus possesses glucose-lowering activities70. In a 
randomized controlled trial, Aloe vera gel complex reduced body weight, body 
fat mass, and insulin resistance in obese pre diabetes and early non treated 
diabetic patients. One study discussed the efficacy of aloe-emodin-8-O-
glycoside isolated from Aloe vera gel in enhancing glucose transport by 
modulating the proximal and distal markers involved in glucose uptake and its 
transformation into glycogen. 
Trace elements present in Aloe vera play a very important role in glucose 
metabolism. The role of inorganic elements like Cr, Zn, Fe, Cu, and Mn 
improved the impaired glucose tolerance and their indirect role of management 
of diabetes mellitus71. Magnesium is one of the important mineral which takes 
part in the carbohydrate and fat metabolism. It plays a role in the insulin release 
and there is a chance of diabetes mellitus in its deficiency. Zn is a versatile 
element in diabetes as a cofactor for insulin and also enhances the effectiveness 
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of insulin. Potassium is necessary for the optimal insulin secretion and its 
depletion can result in reduced glucose tolerance. Thus, trace elements of aloe 
vera gel extract potentiate the antidiabetic activity of this plant. 
So it could be possible that by various mechanisms, like modulating the 
glucose uptake, antioxidant effect due to the presence of flavonoids, vitamins 
and potentiation of insulin action by the presence of trace elements, extract of 
aloe vera gel has antihyperglycemic property with statistically significant fall in 
blood glucose level. 
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CONCLUSION 
Diabetes mellitus is a major public health problem. India has been 
severely affected by the global diabetes epidemic and there is a significant 
increase in the burden of the disease. There is clear evidence to show that 
diabetes prevalence is rapidly increasing, especially in urban India. 
Accordingly, diabetes related complications are also on the rise and 
contribute significantly to overall morbidity and mortality. The low levels of 
education and poor awareness of the disease in the country are enhancing its 
impact on health of the population. 
Early identification and treatment at grass root level can bring down the 
morbidity and mortality. Pharmacotherapy is the corner stone in the management 
of diabetes mellitus and by combining with non-pharmacological therapy, 
diabetes is almost controllable now. 
Even though various groups of medicine are currently available, no drug 
is free from adverse effects. Tolerability, safety at over doses is also a problem 
with many antidiabetic drugs. Hence an ideal drug exhibiting better safety and 
tolerability, which controls diabetes most efficiently is sought for. 
Many effective drugs have come from botanical sources. Already natural 
products like Allium cepa, Allium sativum and many are effective in controlling 
diabetes mellitus. In this present study, aloe vera gel which was used for various 
illnesses as traditional medicine was evaluated for its antihyperglycemic effect 
in albino rats. 
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It was observed that aloe vera gel extract at 200 mg/dl and 400 mg/dl 
produce statistically significant reduction in blood glucose level in 
streptozotocin induced diabetic rats when compared with control group but not 
in normal adult male albino rats. 
The study objective has been achieved. Further studies need to be done 
with more number of animals and different experimental models, to know the 
exact molecular and biological mechanism behind aloe vera gel as an 
antihyperglycemic. Identification and separation of the active principle that is 
responsible for the antihyperglycemic effect has to be further evaluated. 
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MASTER CHART 
 
 
  
MASTER CHART 
 
 
The blood glucose levels in diabetic rats in mg/dl on day 1 
S No CONTROL STANDARD TEST 1 TEST 2 
RAT-  1 253 116 242 240 
RAT-  2 257 108 248 246 
RAT - 3 260 112 251 250 
RAT- 4 254 107 247 246 
RAT- 5 262 114 245 244 
RAT-  6 260 109 253 251 
 
 
 
 
 
 
 
 
  
 
 
The blood glucose levels in diabetic rats in mg/dl on day 7 
S No CONTROL STANDARD TEST 1 TEST 2 
RAT- 1 267 97 184 169 
RAT- 2 265 92 178 172 
RAT- 3 264 94 182 170 
RAT- 4 262 88 180 168 
RAT- 5 267 92 183 173 
RAT- 6 265 87 179 176 
 
 
 
 
 
 
 
 
 
 
 
 
 
The blood glucose levels in diabetic rats in mg/dl on day 14 
S No CONTROL STANDARD TEST 1 TEST 2 
RAT- 1 262 76 169 162 
RAT- 2 266 68 172 166 
RAT- 3 262 78 174 160 
RAT- 4 268 75 167 159 
RAT- 5 265 67 177 166 
RAT- 6 270 77 178 158 
 
                                                                                    
 
 
 
                                                                         
  
  
 
 
 
ABBREVIATION 
  
ABBREVIATION 
 
DM   –  DIABETES MELLITUS 
ROS   –  REACTIVE OXYGEN SPECIES 
JNK/SAPK  –  c-JUN N-TERMINAL KINASE 
NF-κB  –  NUCLEAR FACTOR kappa B 
MAPK  –  MITOGEN ACTIVATED PROTEIN KINASE 
GL   –  GLIBENCLAMIDE 
ATP   –  ADENOSINE TRIPHOSPHATE 
Ca2+  –  CALCIUM 
Cr   – CHROMIUM 
Mn   –  MANGANESE  
Zn   – ZINC 
STZ   –  STREPTOZOTOCIN 
NAD   –  NICOTINAMIDE ADENINE DINUCLEOTIDE 
HLA   –  HUMAN LEUKOCYTE ANTIGEN 
TCF7L2  –  TRANSCRIPTION FACTOR 7 LIKE 2 
GLUT2  –  GLUCOSE TRANSPORTER 2 
GLP   –  GLUCAGON LIKE PEPTIDE 
CFA   –  COMPLETE FREUND’S ADJUVANT 
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